Medications for Alcohol Use Disorder

Alcohol use disorder (AUD) is one of the most common and most undertreated substance use disorders in the United States. One of the reasons it is undertreated is a widespread, inaccurate belief, among patients, families, and sometimes clinicians, that medication is not a major part of the treatment. In 2023, a JAMA systematic review and meta-analysis reconfirmed that naltrexone and acamprosate are first-line pharmacotherapy for moderate-to-severe AUD.¹ Both are prescribed in primary care and outpatient substance use settings. Neither requires a residential admission.

What follows is a plain-language walk through the medications with the strongest evidence, how they work, who they fit, and what the realistic expectations are.

The big picture

Most medications for alcohol use disorder do one of three things:

1. Reduce the rewarding experience of drinking, so that over time drinking feels less compelling (naltrexone).
2. Reduce the withdrawal-related brain state that drives ongoing drinking in people who have become physically dependent (acamprosate, gabapentin, topiramate).
3. Create an aversive physical reaction to drinking that deters it through negative consequences (disulfiram).

None of these are magic. Effect sizes for the first-line medications are real but modest, people often describe the experience as "making it easier to stop or cut back" rather than "removing the desire to drink entirely." That is what the research supports, and calibrated expectations are part of a good plan.

Naltrexone

What it does: Blocks the opioid receptors in the reward system that are partly responsible for the rewarding experience of alcohol. Does not cause withdrawal when the person drinks, does not cause nausea, does not require abstinence to start.

Formulations:

• Oral naltrexone, 50 mg/day. Taken daily.
• Extended-release injectable naltrexone (Vivitrol), 380 mg IM monthly.
• Targeted ("Sinclair") dosing, 50 mg taken approximately one hour before anticipated drinking, rather than on a daily schedule.

Evidence: The JAMA 2023 meta-analysis found oral naltrexone 50 mg/day produced a number needed to treat (NNT) of approximately 18 to prevent return to any drinking, and reduced heavy drinking days. The evidence base includes the VA/DoD clinical practice guideline, which rates naltrexone as "Strong for" in AUD.¹²

The Sinclair Method specifically: Using naltrexone approximately 60 minutes before drinking, rather than as a daily abstinence-maintenance medication, is designed to gradually extinguish the reinforcement loop between drinking and reward. Advocacy materials sometimes cite a 78% success rate, which traces to Finnish clinic cohort data and has not been replicated at that magnitude in independent randomized trials. The defensible headline is the independent effect size from the Cochrane and JAMA analyses, modest but clinically meaningful reductions in heavy-drinking days.¹³⁴

Who it fits: Most people with moderate-to-severe AUD, particularly people with pronounced craving patterns. Also useful for people pursuing moderation rather than abstinence. Contraindicated in people currently using opioids (it will precipitate withdrawal).

Side effects and cautions: Nausea and headache are the most common. Liver enzymes are monitored. Not appropriate for patients with acute hepatitis or hepatic failure.

Acamprosate (Campral)

What it does: Thought to work on the glutamate-GABA balance that is disrupted in physical alcohol dependence. Reduces the protracted withdrawal symptoms, sleep disturbance, anxiety, irritability, that often drive return to drinking in the weeks and months after someone stops.

Formulation: 666 mg three times daily (three pills, three times a day).

Evidence: JAMA 2023 meta-analysis found NNT ≈ 11 to prevent return to any drinking among patients who had achieved initial abstinence.¹ The strongest effect is during the early to middle months of abstinence, not during active drinking.

Who it fits: Patients who have already stopped drinking (at least a few days abstinent) and want to reduce the likelihood of return. Works well in combination with outpatient therapy. Particularly useful for patients whose return to drinking is driven by protracted withdrawal rather than acute craving.

Side effects and cautions: Diarrhea is the most common side effect. Adjusted doses for patients with significant renal impairment.

Gabapentin (off-label)

What it does: Thought to work on GABAergic and calcium channel systems involved in alcohol withdrawal and craving. Used off-label for AUD; has been studied in multiple randomized trials.

Formulations and doses: Typically titrated to 900 to 1800 mg/day in divided doses. Some protocols use doses up to 3600 mg/day.

Evidence: Moderate evidence for reducing heavy drinking days, particularly in patients with a history of alcohol withdrawal symptoms. Useful when first-line agents are contraindicated or not tolerated.

Who it fits: Patients with a pronounced withdrawal-driven pattern, patients with co-occurring anxiety, patients for whom first-line agents are contraindicated.

Side effects and cautions: Sedation, dizziness, edema. Misuse potential is real and has been increasingly documented; careful prescribing is warranted.

Disulfiram (Antabuse)

What it does: Inhibits an enzyme in alcohol metabolism, so that drinking while taking disulfiram produces an acute unpleasant reaction (flushing, nausea, heart racing). Works as a deterrent.

Formulation: 250 mg daily (sometimes 500 mg).

Evidence: Effective only when administration is observed. Patient-self-administered disulfiram has minimal evidence of benefit because patients who do not want to have the reaction simply do not take the pill. Observed or supervised administration (by a family member, partner, or clinic) changes the calculus.⁵

Who it fits: Patients who are motivated for abstinence, are willing to accept a supervised administration arrangement, and have no contraindications. Not appropriate during active drinking, for patients with advanced liver or cardiac disease, or for patients who might drink impulsively during the active window (the reaction can be medically dangerous).

Topiramate (off-label)

What it does: Thought to modulate several neurotransmitter systems involved in alcohol reinforcement.

Formulation: Titrated up to 200 to 300 mg/day.

Evidence: Some evidence for reducing heavy drinking days, often cited in the literature as a reasonable alternative when first-line options are not suitable. Cognitive side effects (word-finding difficulty, slowed thinking) limit tolerability for many patients.

Why MAUD is underused

Across primary care and psychiatric settings in the US, fewer than 10% of patients with AUD receive any FDA-approved medication. The underutilization is often attributed to clinician unfamiliarity, patient expectations set by abstinence-oriented programs that do not discuss medication, and a cultural hangover from the idea that pharmacotherapy is "not real recovery."

The evidence does not support this hesitation. For moderate-to-severe AUD, medication plus behavioral support is the standard of care.

What the medications do not do alone

As with medications for opioid use disorder, the medications for alcohol use disorder are part of a plan. A typical outpatient plan includes:

• One of the above medications, matched to the patient's pattern.
• Outpatient therapy, cognitive behavioral therapy for substance use, motivational enhancement, or a group program. See CBT for SUD.
• Peer or mutual-help engagement, AA, SMART Recovery, Moderation Management, as the patient finds useful.
• Treatment of co-occurring conditions, depression, anxiety, insomnia, chronic pain.
• Monitoring, primary care labs, check-ins, and as-needed titration of the medication.

Withdrawal first, medication after

A critical safety note: patients with moderate-to-severe physical alcohol dependence need medically supervised withdrawal management before or during the early phase of medication treatment. Alcohol withdrawal can be medically dangerous, and at the higher end it can be fatal. For patients with significant physical dependence, the initial clinical priority is safe withdrawal, which can occur in outpatient settings with appropriate clinician oversight (see ASAM's Clinical Practice Guideline on Alcohol Withdrawal Management) or, for higher-acuity cases, in a residential or hospital setting.

This is not a DIY project. Articles on this site describe ambulatory withdrawal management as clinician-supervised care, not as self-directed tapering. If the picture involves daily heavy drinking, a history of withdrawal symptoms, or prior seizures, the first call is to a clinician, not to a pharmacy.

How to start

1. Get an assessment. Primary care, a psychiatrist, or a licensed outpatient substance use clinician. Ask specifically about medication options.
2. Choose a medication with your prescriber. The choice depends on the pattern, whether you are pursuing abstinence, moderation, or stabilization; whether you are already abstinent or still drinking; whether you have had withdrawal symptoms; whether you have co-occurring conditions.
3. Combine with behavioral support. Medication alone outperforms no medication. Medication plus an outpatient therapy or mutual-help group outperforms medication alone.
4. Expect modest effects and stay with the plan. Calibrated expectations help. The medication is often the thing that makes change sustainable; it is rarely the thing that feels dramatic on a day-to-day basis.

The bottom line

For moderate-to-severe alcohol use disorder, medication is standard-of-care. Naltrexone and acamprosate are first-line, with gabapentin, disulfiram, and topiramate in supporting roles. All of them are prescribed in primary care and outpatient settings. None of them requires a residential admission. If you have been told that medication is not part of the plan, or that it is not "real recovery," that framing is out of step with the current evidence.

What to read next

• Ways to Avoid Rehab: The Evidence-Based Guide
• Medications for Opioid Use Disorder
• The ASAM 4th Edition Criteria, Explained for Families

Sources